Clinical Trial: Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
Study Status: Completed
Recruit Status: RECRUITING
Condition: Grade 3b Follicular Lymphoma
Study Type: INTERVENTIONAL
Official Title: Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients With Relapsed/Refractory Large B-Cell Lymphoma
Brief Summary:
This phase 2 trial studies the side effects and best dose of tazemetostat and zanubrutinib in combination with tafasitamab and lenalidomide, and to see how well these combinations work in treating patients with large B-cell lymphoma that returned or did not respond to earlier treatment.Tazemetostat is in a class of medications called EZH2 inhibitors.It helps to stop the spread of cancer cells.Zanubrutinib is in a class of medications called kinase inhibitors.It works by blocking the action of the abnormal protein…
Read more